Derivation of human embryonic stem cell lines from parthenogenetic blastocysts

Qingyun Mai^{1,*}, Yang Yu^{1,2,3,*}, Tao Li¹, Liu Wang², Mei-jue Chen⁴, Shu-zhen Huang⁴, Canquan Zhou¹, Qi Zhou²

¹Reproductive Medical Center, the First Affiliated Hospital of SUMS University, Guangzhou 210029, China; ²State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing 100101, China; ³Graduate University of Chinese Academy of Sciences, Beijing, China; ⁴Ministry of Health Key Lab of Embryo Molecular Biology, Institute of Medical Genetics, Shanghai Jiao Tong University School of Medicine, Shanghai 200040, China

Parthenogenesis is one of the main, and most useful, methods to derive embryonic stem cells (ESCs), which may be an important source of histocompatible cells and tissues for cell therapy. Here we describe the derivation and characterization of two ESC lines (hPES-1 and hPES-2) from *in vitro* developed blastocysts following parthenogenetic activation of human oocytes. Typical ESC morphology was seen, and the expression of ESC markers was as expected for alkaline phosphatase, octamer-binding transcription factor 4, stage-specific embryonic antigen 3, stage-specific embryonic antigen 4, TRA-1-60, and TRA-1-81, and there was absence of expression of negative markers such as stage-specific embryonic antigen 1. Expression of genes specific for different embryonic germ layers was detected from the embryoid bodies (EBs) of both hESC lines, suggesting their differentiation potential *in vitro*. However, *in vivo*, only hPES-1 formed teratoma consisting of all three embryonic germ layers (hPES-2 did not). Interestingly, after continuous proliferation for more than 100 passages, hPES-1 cells still maintained a normal 46 XX karyotype; hPES-2 displayed abnormalities such as chromosome translocation after long term passages. Short Tandem Repeat (STR) results demonstrated that the hPES lines were genetic matches with the egg donors, and gene imprinting data confirmed the parthenogenetic origin of these ES cells. Genome-wide SNP analysis showed a pattern typical of parthenogenesis. All of these results demonstrated the feasibility to isolate and establish human parthenogenetic ESC lines, which provides an important tool for studying epigenetic effects in ESCs as well as for future therapeutic interventions in a clinical setting.

Keywords: parthenogenetic activation, human embryonic stem cells, pluripotency, karyotype, differentiation

Cell Research (2007) 17:1008-1019. doi: 10.1038/cr.2007.102; published online 11 December 2007

Introduction

Human embryonic stem cells (hESCs) have tremendous potential for cell therapy of human diseases such as neurodegenerative disorders [1], and in regenerative medicine

[2]. Since the first derivation of human embryonic stem cell lines from IVF blastocysts [3], the field of hESC research has generated substantial interest, although certain obstacles still remain including limited sources of oocytes and controversial ethical issues [4] that have hindered further advancement. Parthenogenetic stem cells are regarded as a substitute for ES lines derived from somatic cell nuclear transfer (SCNT), with higher efficiency and less ethical controversy, and proven results in mouse and non-human primate models [5, 6].

Parthenogenetic stem cell lines have been extensively reported in mouse [7] and non-human primate models [8, 9] and recently in human [10, 11]. Parthenogenetic stem cells have been successfully differentiated into neuronal

*These authors contribute equally to this work.

Correspondence: Qi Zhou¹, Canquan Zhou², Shu-zhen Huang³

¹Tel/Fax: +86-10-64807299; E-mail: qzhou@ioz.ac.cn

²Tel/Fax: +86-20-87786029; E-mail: zhoucanquan@hotmail.com

³Tel: +86-21-62790545; Fax: +86-21-62475476; E-mail: szhuang1@yahoo.com

Received 26 September 2007; revised 7 November 2007; accepted 19 November 2007; published online 11 December 2007

cells in a defined differentiation system in monkey *in vitro* [8], and another report showed that dopamine neurons derived from parthenogenetic ESCs have long term survival after transplantation into rodent and primate brains [6]. For patients with Parkinson's or other neurodegenerative disorders (especially in female patients), there may be hope for autologous and personalized stem cell treatments of the otherwise devastating diseases. However, one report has suggested that the loss of epigenetic imprinting may limit the effectiveness of stem cells derived from parthenogenetic embryos [12].

As paternally imprinted genes were shown to be stable in androgenetic (two paternal chromosome sets) stem cells [13], maternal factors seem to have a major effect on the instability of imprinted genes [14]. In parthenotes all genetic material originates from the maternal genome, and the resulting stem cells would demonstrate only maternal patterns of gene imprinting. Thus, parthenogenetic ESCs can be an invaluable source of material to study mechanisms of epigenetic regulation, as well as to explore disease mechanisms and their treatment, since many severe diseases including cancer [15] and Beckwith-Wiedeman syndrome [16] are believed to be influenced by imprinting.

In this study, we reported the establishment of two human embryonic stem cell lines from parthenogenetically activated embryos *in vitro* and subsequent observation of those cells over more than 100 passages. We verified the parthenogenetic origin of these cell lines and performed detailed characterization of the pluripotency of one of the lines.

Materials and Methods

Informed consent for egg donation

All of the egg donors were on the assisted reproductive technology (ART) cycle. No financial benefit was involved in the donation process. The egg donors were informed of all details of the procedure, including egg utility and research destination, and signed a series of informed consent documents voluntarily. We guaranteed that all of the eggs were used in basic scientific research, and not for reproductive purposes.

All of the ART and therapeutic cloning procedures followed closely the guidelines legislated and posted by the Ministry of Health of the People's Republic of China. Normally only 1-4 eggs were received and selected randomly from each donor, so that it would not jeopardize the future clinical treatment or reproductive capability of the donors.

Donor superovulation and oocyte collection

Before subject to superovulation, each patient underwent basic physical examination and was tested to rule out human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and contagious venereal diseases. Eligible patients received 1.3 mg GnRH-agonist (Dipherin) at mid-luteal phase and recombined follicle stimulating hormone (rFSH) (gonal-f, Serono, Sweden) at

a dose of 150-300IU/day from day 3 of menstrual cycle for the growth of multiple follicles. When the diameter of dominant follicles reached 18 mm, a single 10 000 IU dose of HCG (Profasi, Serono, Sweden) was administered and transvaginal follicular aspiration was performed 36 h later.

Parthenogenetic activation and embryo culture

Donated eggs were selected randomly, and cultured in a humidified atmosphere at 37 °C with gas mixture consisting of 90% N₂, 5% O₂ and 6% CO₂. Prior to activation, granule cells around individual oocytes were removed by brief exposure to 80 IU/ml hyaluronidase (Sigma) (~ 30 s) followed by sequential mechanical manipulation in HEPES buffered medium (Quinn'S Advanlage™ Manipulation Medium). Mature oocytes were subjected to the following activation procedure, and immature oocytes were cultured in cleavage medium (Quinn'S Advanlage™ Cleavage Medium). After culturing for 30 min in a humidified atmosphere at 37 °C with gas mixture (90% N₂, 5% O₂ and 6% CO₂), mature oocytes were subjected to sequential activation treatments. First, electric activation was performed with electric pulse in electrofusion medium containing 0.3 M mannitol (with 0.1 mM MgSO₄·7H₂O, 0.1 mg/ml polyvinyl alcohol, 3 mg/ml human serum albumin, 0.05 mM CaCl₂·2H₂O). After rinsing in HEPES buffer medium (Quinn'S Advanlage™ Manipulation Medium), the oocytes were transferred into 5 µM ionomycin (Sigma) for 5 min and then incubated in cleavage medium (Quinn'S Advanlage™ Cleavage Medium) with 2 mM 6-dimethylamino-purine for an additional 5 h. The activated oocytes were cultured in the cleavage medium (Quinn'S Advanlage™ Cleavage Medium); pronuclear cells were observed with an inverted microscope (Nikon Co.) 18 h later and the embryos were transferred into blastocyst culture medium (Quinn'S Advanlage™ Blastocyst Medium) two days later for another 3-4 days. The embryos were observed every 24 h and developmental efficiency was calculated.

Human stem cells isolation and culture

Embryos developed to blastocyst stage at the fifth day after activation; one or two days later, the blastocysts reached the hatching stage and an immunosurgery method was used to isolate the inner cell mass (ICM) as previously described [17]. Specifically, the zona pellucida was removed by 0.5% pronase A (Sigma) treatment, and the blastocyst was incubated with horse antiserum to human spleen cells followed by exposure to guinea pig complement. Trophectoderm cells were detached from the ICM by gently pipetting the zona-free blastocysts. The isolated ICMs were plated on the mitomycin-C irradiated mouse embryonic fibroblast cells (MEFs) for about 5-9 days and primary ESC colonies were then dissociated mechanically and cultured in human ES cell culture medium consisting of 80% Knockout-DMEM (Gibco), 20% Serum-Replacement (Gibco), 1 mM glutamine (Sigma), 1% nonessential amino acid (Gibco), 0.1 mM 2-mercaptoethanol (Sigma), 50 UI/ml penicillin (Sigma), and 50 UI/ml streptomycin (Sigma) mixture as previously described [18]. Human ES cell lines established from IVF embryos were used as controls. One of these IVF lines (IVF-1) was fully characterized and reported previously [18].

The primary colonies were cultured for 5-9 days and the ES cells were selected, picked up, and replated on new feeder cells. When the ES cells appeared to proliferate stably, the ES colonies were dissociated every 4-5 days by mechanical or digestive methods. All of the ESCs were cultured under 37 °C, 5% CO₂ in a humidified atmosphere.

Characterization of human parthenogenetic ES cell lines

For immunofluorescence staining and assaying of alkaline phosphatase (AP), hPES cells were plated on glass coverslips coated by MEF cells and cultured for 3–4 days. The ES cell clones were fixed by acetone, and blocked with 10% goat serum in PBS (Sigma) for 1 h, and then incubated with primary antibodies overnight at 4°C. Antibody localization was performed using rabbit anti-mouse immunoglobulin secondary antibody conjugated to fluorescein isothiocyanate. Specimens were observed with a fluorescent microscope. The primary antibodies included antibodies to stage-specific embryonic antigen 3 (SSEA-3), SSEA-4, SSEA-1 (Developmental Studies Hybridoma Bank at the University of Iowa), TRA-1-60 (Chemicon), and TRA-1-81 (Chemicon). Nuclei of ESCs were stained with Hoechst 33342 (Sigma).

Alkaline phosphatase (AP) activity was observed by the Gomori modified method. The ES clones were fixed by cold acetone for 10 min and incubated with AP incubation medium containing 2% sodium glycerophosphate, 2% barbital sodium, 2% chloratum potassium and 2% magnesium sulfate for 3 h at 37 °C, and subsequently incubated in 5% cobaltous nitrate for 5 min and in 1% ammonium sulfide for 1 min.

Gene expression profile analysis

Expression of imprinted genes of hPES cells was analyzed by RT-PCR. Total RNA was extracted using TRIzol (Invitrogen, Grand Island, NY). cDNA was synthesized from ~1 mg of total RNA using SuperScript II reverse transcriptase (Invitrogen, Grand Island, NY) and was subjected to PCR amplification with primers for *Oct-4*, *Rex1*, *Sox2*, *Nanog*, *NF68KD*, *α-fetoprotein*, *albumin*, *H19*, *h-Ube3A*, *h-Snrpn*, and *Igf-2* (Table 1). *β-actin* was used as a control. PCR products were size-fractionated by 1% agarose gel electrophoresis and visualized by ethidium bromide staining. Final analysis was obtained in an image analyzer (Biorad).

Karyotyping

hPES colonies were incubated with 0.2 μg/ml colchicin (Invitrogen) for 2 h at 37 °C. Cells were collected and trypsinized, washed with PBS, and incubated with 0.075 mol/L potassium chloride for 10 min at 37 °C. Cells were fixed with methanol:glacial acetic acid (1:3)

three times and dropped onto glass slides. Chromosome spreads were Giemsa banded and photographed. The karyotypes of ES cells were detected every 10 passages. Karyotypes were assessed by normal G-banding procedure and 50 metaphase II spreads were examined for each sample, and a normal karyotype would show normal chromosome numbers and G-banding patterns in the spreads examined.

Assessment of the differentiation capacity in vitro and in vivo

Embryoid body (EB) method was used to assess the differentiation ability *in vitro* of hPES cells via specific gene expression. hPES cells were removed from culture dishes using 1 mg/ml collagenase IV and cultured in suspension condition. Spontaneous EBs were grown in medium consisting of 80% Knockout-DMEM, supplemented with 20% serum replacement, 0.1 mM 2-mercaptoethanol, and 1% nonessential amino acids. After 5–14 days, all of the differentiated samples from EBs were collected, and RT-PCR was performed to analyze specific gene expression for the three embryonic germ layers—mesoderm, endoderm, and ectoderm.

Teratoma production was used to assess the differentiation ability *in vivo* of hPES cells. About 5–6 million undifferentiated hPES cells from passages 10, 15, and 20 were harvested and injected into the back muscle of 6-week-old male SCID-mice. After 3 months, the mice were sacrificed. Various tissues from teratoma were dissected, fixed in Bouins overnight, processed, and sectioned according to standard procedures [19] and counterstained with either hematoxylin and eosin or Weigert's stain. Sections were examined using bright field light microscopy and photographed as appropriate.

STR Typing

Genomic DNA samples were extracted from the ES cells, peripheral blood of oocyte donors, the teratomas using phenol-chloroform method [20]. Sixteen STR loci were co-amplified in one PCR reaction. Alleles of STR loci were distinguished by fluorescence detection following electrophoretic separation. STR typing process was performed according to manufacturer's recommendations using the PowerPIEX 16 system (Promega, USA). The ABI PRISM 310 Genetic Analyzer was used for fluorescence detection of amplified fragments.

Table 1 PCR primers used to detect gene expression in hES cells

Gene	Sense (5'–3')	Antisense (5'–3')	Size (bp)
<i>OCT-4</i>	CTTGCTGCAGAAGTGGGTGGAGGAA	CTGCAGTGTGGGTTTCGGGCA	198
<i>Nanog</i>	CAGCTGTGTGTACTCAATGATAGATT	CAACTGGCCGAAGAATAGCAATGGTGT	142
<i>SOX2</i>	GCCTGGGCGCCGAGTGGA	GGGCGAGCCGTTTCATGTAGGTCTG	443
<i>REX1</i>	GCTGACCACCAGCACACTAGGC	TTTCTGGTGTCTTTGCCCG	298
<i>NF68KD</i>	TCCCCTGAAGAAATTGGTTAAAAT	GAGTGAAATGGCAGCATACCTA	473
<i>α-feto-protein</i>	GCTGGATTGTCTGCAGGATGGGGAA	TCCCCTGAAGAAAATTGGTTAAAAT	486
<i>Albumin</i>	TGCTTGAATGTGCTGATGACAGGG	AAGGCAAGTCAGCAGCCATCTCAT	302
<i>H19</i>	TCCGGCCTTCCTGAACAC	CATCCCGCTGGAGGAGCT	410
<i>UBE3A</i>	TTAGGGAGTTCTGGGAAATCGTT	GTAAGGGACACTATCACCACCAA	400
<i>h-SNRPN</i>	TGCTGCCCTTTTACCAG TG	TCATGATTGCTGTTCCACCAA	443
<i>IGF-2</i>	AAGCTCTGTGGGACCTCTTG	CTCGAAGCGTTTGGATCTC	467
<i>β-actin</i>	ATTGGCAATGAGCGGTTCCG	AGGGCAGTGATCTCCTTCTG	200

SNP analysis

SNP genotyping

Genomic DNA samples were purified from cell lines using phenol/chloroform extraction and ethanol precipitation, and submitted to the Penn Microarray Facility (University of Pennsylvania, Philadelphia PA) for genotyping. Target DNA preparation and microarray processing for the Affymetrix 250K Sty SNP Mapping GeneChips (Affymetrix, Santa Clara, CA) were conducted according to the manufacturer's protocol (Mapping 500K Assay Manual, www.affymetrix.com). Briefly, after digestion of genomic DNA with StyI, complexity reduction PCRs produced over 100 µg of target DNA per sample, which was fragmented by DNase treatment and biotinylated by terminal transferase. Microarrays were hybridized overnight, then washed and stained using FS450 Fluidics Stations and scanned in a GeneChip 3000 7G scanner.

SNP data analysis

The Affymetrix GCOS package with BRLMM algorithm was used to assign genotype calls for 238 304 SNPs distributed throughout the genome with median intermarker distance of 5.2 kb (mean 12.2 kb). Tabulated calls were ordered by SNP physical map coordinate, and the number of heterozygous calls was summed within a window of 1 000 contiguous SNPs. This value was divided by the DNA length in megabase-pairs encompassed by the window, producing a normalized heterozygosity rate suitable for comparison within and between chromosomes. The average heterozygosity rate for every 5 Mb interval distal from the centromere was calculated for each chromosome and color coded to represent differences in levels among samples.

Results

Parthenogenetic embryo development and derivation of ES cell lines

Nineteen oocytes prepared shortly after donation by 10

ART patients were artificially activated *in vitro*. After removal of cumulus cells only matured metaphase II oocytes with distinct first polar bodies were taken for a two-step activation procedure. Electric-stimulation and chemical agent stimulation were performed sequentially. Sixteen oocytes were activated and pseudo-pronuclei were observed after an additional 18 h in culture. Fourteen activated oocytes cleaved but the developmental ability thereafter decreased significantly resulting in four blastocysts after culturing for 5-6 days (Table 2). The surviving blastocysts were able to expand and hatch similar to normal fertilized embryos (Figure 1).

Three parthenogenetic blastocysts had visible ICM, and were used for derivation of ESC lines. One of the three ICMs was lost at day 3; the other two were capable of growing and were mechanically dissected after 7-9 days, and the resulting cell lines were named hPES-1 and hPES-2. Characterization and identification of these ESC lines were performed after primary hPES cells were propagated for more than 10 passages (Table 3). We will describe the complete analysis for the hPES-1 line in this paper as an example.

Characteristics of hPES cells

hPES colonies demonstrated stem cell morphology, and displayed traits of a normal stem cell line, including high nuclear/cytoplasm ratio, and tightly packed colonies when observed under the inverted microscope (Figure 2 and Table 4). In addition, these colonies showed high levels of AP activity (Figure 2 and Table 4). The hPES colonies expressed stem cell positive cell surface markers includ-

Table 2 Developmental efficiency of *in vitro* activated human parthenogenetic oocytes

Donor	No. of oocytes donated	No. of activated oocytes #	Activated oocyte develop to: (%)					ES line
			2-cell	4-cell	8-cell	Morula	Blastocyst	
1	1	1	1	1	1	1	1	hPES-1
2	3	2	2	1	1	0	0	/
3	4	4	4	4	4	2	1	/
4	4	3	3	1	1	0	0	/
5	1	1	1	1	1	1	1	/
6	1	0	0	0	0	0	0	/
7	1	1	0	0	0	0	0	/
8	1	1	1	1	0	0	0	/
9	1	1	1	0	0	0	0	/
10	2	2	1	1	1	1	1	hPES-2
Total	19	16 (84.2)	14 (87.5)	10 (62.5)	9 (56.3)	5 (31.3)	4 (25.0)	

Except for the 2-cell stage (which is based on No. of oocyte donated), developmental efficiency is defined by percentages based on number of activated oocytes for the rest of the stages.

#Activated oocytes were evaluated by pronuclei formation.

Figure 1 Morphologies of parthenogenetic blastocysts. (A) Expanding blastocyst; (B) Hatching blastocyst; (C) Hatched blastocyst.

Table 3 Derivation efficiency of hES cell lines from IVF and parthenogenetic blastocysts

Type of ES cell	No. of blastocysts	No. of outgrowth (%)	No. of derived ES lines (%)
IVF-hES	36	9 (25.0)	4 (11.1)
hPESC	3	2 (66.7)	2 (66.7)

Table 4 Gene expression profile of hEC lines

ES Cell Lines	AL P	E B	Pluripotent genes				Cell surface markers				
							Positive markers				Negative marker
			Oct4	Nanog	Rex-1	Sox-2	SSEA-3	SSEA -4	TRA1-60	TRA-1-81	SSEA-1
IVF-hES (4)	+	+	+	+	+	+	+	+	+	+	-
HPES-1	+	+	+	+	+	+	+	+	+	+	-
HPES-2	+	+	+	+	+	+	+	+	+	+	-

ing SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81, but not the negative cell surface markers, including SSEA-1, as expected (Figure 2 and Table 4).

Expression of important pluripotency related genes was detected by RT-PCR and positive signals for *Oct-4*, *Rex1*, *Sox2* and *Nanog* were shown in both hPES cell lines, as well as in the ESCs derived from IVF embryos (Figure 2 and Table 4).

Differentiation potential of hPES cells

hPES cells were capable of differentiating to EB *in vitro* when cultured in suspension conditions. After spontaneous differentiation for 10-15 days, these EBs were used for further RT-PCR analysis. Genes uniquely expressed in all three embryonic germ layers were shown to be expressed, including albumin (endoderm), α -fetoprotein (endoderm), Glu2 (endoderm), α -cardiac actin (mesoderm) and neurofilament (ectoderm) (Figure 3).

Differentiation ability of hPES cells *in vivo* was evalu-

ated by teratoma formation. $5-6 \times 10^5$ stem cells were injected into the back muscle of SCID-mice. While hPES-2 cells failed to form any teratoma, teratomas were observed after 3 months with cells from hPES-1 cell line (of different passages). Histopathology of the resulting teratomas revealed the presence of various tissues including glandular and intestinal epithelia (endoderm), cartilage and interstitial cells (mesoderm), and squamous cells (ectoderm) (Figure 4). These results demonstrated that hPES-1 was capable of differentiation *in vivo* into all three embryonic germ layers, and thus all cell types in human.

Identification of parthenogenetic origin

In normal fertilized embryos differential expression occurs in maternally or paternally imprinted genes. Therefore the lack of paternal imprint patterns would be useful evidence of parthenogenetic origin. Expression of imprinted genes was tested in both hPES cell lines and IVF control lines. Transcription of paternally expressed *SNRPN* and

Figure 2 Morphology, AP and Immunostaining of stem cell markers for hPES-1 cell line. (A) Morphology of hPES-1 colony under invert microscope; (B) AP staining of hPES-1; (C) SSEA4; (D) SSEA3; (E) TRA-1-60; (F) TRA-1-81; (G) SSEA1. (C-G) Listed are optical, confocal images and the corresponding Hoechst staining for the hPES-1 cells.

IGF-2 genes was not detected, whereas maternally expressed *UBE3A* and *H19* were observed in hPES-1 (Figure 5). The expression of all of the above imprinted genes was

detected in IVF controls.

Karyotyping was performed at every 20 passages from passages 20 to 120 for hPES-1 and hPES-2. The 46 XX

Figure 3 RT-PCR analysis of EBs of hPES cells for differentially expressed genes from three embryo germ layers *in vitro*. Data from the hPES-1 line are shown: Lanes: 1: Albumin; 2: a-cardiac actin; 3: a-fetoprotein; 4: Glu2; 5: GAPDH; 6: NF-68KD. No primer and no template PCR controls were negative (data not shown)

karyotypes were consistent with the hPES origin from a female donor; P 40 data from hPES-1 is shown in Figure 6. No chromosomal abnormality was identified beyond more than 80 passages in hPES-1, indicating that hPES-1 sustained genetic stability through long and repeated propagation *in vitro*. For hPES-2, abnormal karyotypes (e.g. chromosome translocation) were observed more and more frequently beyond passage 50.

To further confirm the autologous origin, an STR study was performed among the hPES lines, lymphocytes from the donors, and the resulting teratoma from hPES-1. Results from 16 DNA loci indicated that hPES-1 was genetically identical to the teratoma and more than 99.85% comparable

Figure 4 Histopathology analysis of teratoma resulting from *in vivo* differentiation of hPES-1 cells. (A) Glandular and intestinal epithelia (endoderm); (B) Cartilage and interstitial cells (mesoderm); (C) Squamous cells (ectoderm).

Figure 5 RT-PCR analysis of the expression of selected imprinted gene expression. Lanes 1-5 are results from hPES-1 cells and lanes 6-10 normal IVF-1 hES cells for the following genes: lanes 1 and 10: β -actin; lanes 2 and 6: h-SNRPNR; lanes 3 and 7: IGF-2; lanes 4 and 8: UBE3A; lanes 5 and 9: H19. No primer and no template PCR controls were negative (data not shown).

rates for every 5 Mb interval distal from the centromeres were calculated and plotted for each chromosome of hPES and IVF control lines at early (P 12), medium (P 40) and late passages (P>70). We described the heterozygosity rate using six arbitrary grades to identify the areas along the chromosome that are more heterozygous in nature.

The pattern of SNP genotypes of hPES-1 revealed that homozygosity predominates at pericentromeric markers and heterozygosity is seen at more distal markers (Figure 7), which resembles very closely the result described recently by Kim *et al.* [11]. In contrast, heterozygosity was observed throughout all chromosomes with all markers with the IVF control line (Figure 7). These data strongly confirmed the parthenogenetic origin of the hPES-1 cell line. Similar results were found for hPES-2.

Discussion

Two human parthenogenetic stem cell lines were successfully derived from parthenogenetic embryos. After artificial activation by a two-step procedure, 4 out of 19

with the lymphocytes from the oocyte donor for hPES-1 (Table 5).

Using the Affymetrix GeneChip Human Mapping 250 K SNP Array, we extensively analyzed the patterns of heterozygosity of hPES and the IVF control lines. Heterozygosity

Figure 6 Karyotyping of parthenogenetic embryonic stem cells. **(A)** hPES-1 at passage 40 (with normal 46 XX karyotype); **(B)** hPES-2 at passage 57. Note: the 46 XX karyotype but with deletions at X (q22q24) and chromosome 1 (q21q25).

Figure 7 Genome-wide SNP Analysis on hES cells using Affymetrix 250K SNP Array. Top: Heterozygosity rate plots for representative chromosomes 1, 11, 13 and 18, with IVF-1 and hES-1 lines at early (P 12 or P 13) and medium passages (P 39 or P 40). Heterozygosity rate is defined in Materials and Methods section. Bottom: Heterozygosity maps for the four samples above at 5 Mb resolution along each chromosome. Heterozygosity rate is indicated by color coding using six arbitrary levels: red, orange, yellow, light blue, blue and dark blue correspond to rate thresholds of 3, 6, 9, 14, 19, 25 and over.

Table 5 STR identification among donor lymphocytes, teratoma and parthenogenetic embryonic stem cells

STR loci	hPES-1	Lymphocyte from donor patient	Teratoma
D3S1358	16	16/17	16
TH01	9	9	9
D21S11	30/31	30/31	30/31
D18S51	14/15	14/15	14/15
Penta E	15/20	15/20	15/20
D5S818	9/11	9/11	9/11
D13S317	10	8/10	10
D7S820	9/12	9/12	9/12
CSFIPO	11/3	11/3	11/3
Penta D	11	11	11
vWA	17/19	17/19	17/19
D8S1179	15	10/15	15
TPOX	9/11	9/11	9/11
FGA	14/15	14/15	14/15
Penta E	19/25	19/25	19/25
Amel	XX	XX	XX

The number listed represents the repeat numbers of allelic ladder components.

initial oocytes developed into blastocysts. Two ESC lines were obtained. We employed a battery of tests to characterize the pluripotent nature of the ESCs and confirmed their parthenogenetic origin. The characteristic was reflected by the hPESs displaying the typical ESC morphology and expression of known human ESC positive markers (SSEA-4, SSEA-3, TRA-1-60, TRA-1-80), and lack of the human ESC negative markers (e.g. SSEA-1) [21, 22].

Self-renewal and pluripotency are the two important features of embryonic stem cells and are reflected in the hPES-1 line as similar proliferation time was maintained during propagation (data not shown), and genetic stability was also proven to be preserved via karyotype analysis. Pluripotency of ESCs is critical for ESC-based therapy. RT-PCR results revealed the expression of key genes such as *Oct-4*, *Rex1*, *Sox2* and *Nanog* that coordinately play central roles suggesting, on a molecular level, the pluripotency of the hPES lines.

Another crucial function for ESCs and therefore for therapeutic cloning is the differentiation potential of the human ESCs. hPES-1 is capable of differentiation into all three germ layers *in vitro* and *in vivo* as measured by RT-PCR from differentiated EBs and histopathology analysis in resulting teratoma. hPES-2, on the other hand, expressed marker genes from all three germ layers from EBs, but failed to form teratoma *in vivo*. Uniparental ESCs were shown to

be able to contribute to proliferating stem cell populations of postnatal aggregation chimeras [23], and differentiation potential of parthenogenetic ESCs was demonstrated in non-human primate models using EB and teratoma analysis [6, 9]. A common problem for parthenogenetic ESCs is the capacity for further differentiation of these cells *in vivo*. Our hPES-1 and hPES-2 demonstrated significant differences in differentiation abilities *in vivo*. Interestingly, Hikichi *et al.* reported improving parthenogenetic ESCs' differentiation potential using a nuclear transfer (NT) technique in mice [24]. Thus, the potential of the parthenogenetic ESCs might be enhanced by NT and other culture techniques to further our understanding and utilization of these cells in stem cell based therapy in human. In addition, while hPES-1 maintained normal karyotypes beyond 80-100 passages, hPES-2 failed to sustain genomic stability. This may suggest micro-abnormalities or other pre-existing factors/conditions in this ES cell line that hindered further ES cell functions (i.e. self renewal and pluripotency). Thus the two parthenogenetic ES cell lines generated here would provide a useful model to study the mechanisms of ESC differentiation and ESC functions.

The mechanism of genomic imprinting is at present not fully understood. The uniparental ESC system provides a useful tool for the studying of epigenetic modifications and imprinting mechanisms such as allele-specific DNA methylation and chromatin structural modifications [14]. In the process of parthenogenesis, the haploid genome was copied to diploid without expelling the polar body (PB), therefore all of the genetic material in the parthenote came from the maternal genome, and lacked paternal imprinting. *SNRPN* (small nuclear ribonucleoprotein polypeptide N) is a mono-allelic paternally expressed gene and has previously been shown to be functionally imprinted in both mouse [25] and human [26]. Another paternally expressed imprinted gene, *IGF2* is regarded as a key regulator for fetal growth control, and is thought to be closely linked to diseases including growth disorders and cancers [27]. *UBE3A* and *H19* genes, on the other hand, have been identified as maternally expressed imprinted genes in human, and as also regarded to contribute to human diseases and tumor growth [28, 29]. A negative RT-PCR result for the two paternally expressed imprinted genes together with a positive result for *UBE3A* and *H19* in hPESs is consistent with a parthenogenesis origin for the hPES cell lines. Failure of development to term of parthenogenetic embryos was thought to be a consequence of having a uniparental genome [30], and although parthenogenetic stem cells were suggested to have limited differentiation potential due to the lack of paternal imprinting [30, 31], modification of specifically imprinted genes was reported to help extend full organismal development and increase the differentiation ability of the ESCs and thus

the ESCs-based cell therapy [32, 33, 34].

STRs (short tandem repeat) are short sequences of DNA with high frequency tandem repeats of 3-7 base pairs, and have been used extensively for parentage testing, forensic identification, and medical diagnostics [35], due to their high polymorphic rates and stable inheritance. STRs are considered an accurate, highly discriminating, sensitive, and rapid technique for DNA typing and genotype identification. Thus, we analyzed the STR polymorphisms of our hPES cells and their egg donors using the PowerPlex® 16 System (Promega). Using an accepted positive threshold for parentage identification [36], our result confirmed that the parthenogenetic ESCs truly originated from the egg donors. This result is consistent with those found by Kim *et al.* [5], that contrary to the presumption of predominant homozygosity in the pES cells, a higher level of heterozygosity was observed due to recombination events prior to the generation of the parthenogenetic ES lines. Nevertheless, the STR confirmed the origin of the derived parthenotes.

A recent report analyzed a human ES cell line initially thought to be generated by SCNT [37], and showed that this line was a result of parthenogenesis [11]. Using high resolution single nucleotide polymorphism (SNP) analysis, Kim *et al.* demonstrated distinct signatures of genetic recombination that distinguish parthenogenetic ES cells from those generated by SCNT. A genome-wide SNP analysis was used as an independent verification of the parthenogenetic nature of the hPES-1 and hPES-2 stem cell lines, and our results resemble closely the parthenogenetic ES cell pattern previously reported. Moreover, while the SCNT-hES-1 line previously reported [37] was not an intentional product of parthenogenesis, our study provides a reliable method for producing and analyzing true human parthenogenetically derived ESC lines since parthenogenesis is still to date more efficient than SCNT to generate human ES cells for cell therapy.

The parthenogenetic stem cells have been shown to be capable of contributing to several mature tissues in chimeric mice [38, 39]. For female patients, it is extremely attractive to use parthenogenetic embryonic stem cells for autologous cell therapy, since ethical concerns and the hazards for collecting and destroying one's normally competent embryos for ES cell derivation can be avoided. Thus, parthenogenetic ES cells have a tremendous potential for cell therapy in clinics and we offer here a useful model and an experimentally verified system for using these cells to study stem cell biology (including epigenetic regulation of ESCs) and explore their potential in disease therapeutics.

Acknowledgments

This study was supported by the Hi-Tech Research

and Development Program of China (863 Program 2006AA02A101).

References

- 1 Lindvall O, Kokaia Z. Stem cells for the treatment of neurological disorders. *Nature* 2006; **441**:1094-1096.
- 2 Vats A, Bielby RC, Tolley NS, Nerem R, Polak JM. Stem cells. *Lancet* 2005; **366**:592-602.
- 3 Thomson JA, Itskovitz-Eldor J, Shapiro S, *et al.* Embryonic stem cell lines derived from human blastocysts. *Science* 1998; **282**:1145-1147.
- 4 Steinbrook R. Egg Donation and Human Embryonic Stem-Cell Research. *N Engl J Med* 2006; **354**:324-326.
- 5 Kim K, Lerou P, Yabuuchi A. Histocompatible Embryonic Stem Cells by Parthenogenesis. *Science* 2006; **315**:482-486.
- 6 Sánchez-Pernaute R, Studer L, Ferrari D, *et al.* Long-term survival of dopamine neurons derived from parthenogenetic primate embryonic stem cells (cyto-1) after transplantation. *Stem Cells* 2005; **23**:914-922.
- 7 Kaufman MH, Robertson EJ, Handyside AH, Evans MJ. Establishment of pluripotential cell lines from haploid mouse embryos. *J Embryol Exp Morphol* 1983; **73**:249-261.
- 8 Cibelli J, Grant K, Chapman K, *et al.* Parthenogenetic stem cells in nonhuman primates. *Science* 2002; **295**:819.
- 9 Vrana K, Hipp J, Goss A, *et al.* Nonhuman primate parthenogenetic stem cells. *Proc. Natl. Acad. Sci. U S A* 2003; **100**:11911-11916.
- 10 Revazova ES, Turovets NA, Kochetkova OD, *et al.* Patient-Specific Stem Cell Lines Derived from Human Parthenogenetic Blastocysts. *Cloning and Stem Cells* 2007; **9**:1-9.
- 11 Kim K, Ng K, Rugg-Gunn P, *et al.* Recombination Signatures Distinguish Embryonic Stem Cells Derived by Parthenogenesis and Somatic Cell Nuclear Transfer. *Cell Stem Cell* 2007; **1**:346-352.
- 12 Hernandez L, Kozlov S, Piras G, Stewart CL. Paternal and maternal genomes confer opposite effects on proliferation, cell-cycle length, senescence, and tumor formation. *Proc Natl Acad Sci USA* 2003; **100**:13344-13349.
- 13 Mann JR, Stewart CL. Development to term of mouse androgenetic aggregation chimeras. *Development* 1991; **113**:1325-1333.
- 14 Allen ND, Barton SC, Hilton K, Norris ML, Surani MA. A functional analysis of imprinting in parthenogenetic embryonic stem cells. *Development* 1994; **120**:1473-1482.
- 15 Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. *Nat Rev Genet* 2006; **7**:21-33.
- 16 Prawitt D, Enklaar T, Gartner-Rupprecht B, *et al.* Microdeletion and IGF2 loss of imprinting in a cascade causing Beckwith-Wiedemann syndrome with Wilms' tumor. *Nat Genet* 2005; **37**:785-786.
- 17 Solter D, Knowles BB. Immunosurgery of mouse blastocyst. *Proc Natl Acad Sci USA* 1975; **72**:5099-102.
- 18 Li T, Zhou CQ, Mai QY, Zhuang GL. Establishment of human embryonic stem cell line from gamete donors. *Chin Med J* 2005; **118**:116-122.
- 19 Klimanskaya I, Chung Y, Becker S, Lu SJ, Lanza R. Human embryonic stem cell lines derived from single blastomeres. *Nature* 2006; **444**:481-485.

- 20 Parayre S, Falentin H, Madec MN, *et al.* Easy DNA extraction method and optimisation of PCR-Temporal Temperature Gel Electrophoresis to identify the predominant high and low GC-content bacteria from dairy products. *J Microbiol Methods* 2007; **69**:431-441.
- 21 Loring JF, Rao MS. Establishing standards for the characterization of human embryonic stem cell lines. *Stem Cells* 2006; **24**:145-150.
- 22 Brivanlou AH, Gage FH, Jaenisch R, Jessell T, Melton D, Rossant J. Setting standards for human embryonic stem cells. *Science* 2003; **300**:913-916.
- 23 Jagerbauer EM, Fraser A, Herbst EW, Kothary R, Fundele R. Parthenogenetic stem cells in postnatal mouse chimeras. *Development* 1992; **116**:95-102.
- 24 Hikichi T, Wakayama S, Mizutani E, *et al.* Differentiation potential of parthenogenetic embryonic stem cells is improved by nuclear transfer. *Stem Cells* 2007; **25**:46-53.
- 25 Cattanach BM, Barr JA, Evans EP, *et al.* A candidate mouse model for Prader-Willi syndrome which shows an absence of *Snrpn* expression. *Nat Genet* 1992; **2**:270-274.
- 26 Glenn CC, Porter KA, Jong MTC, Nicholls RD, Driscoll DJ. Functional imprinting and epigenetic modification of the human *SNRPN* gene. *Hum Mol Genet* 1993; **2**:2001-2005.
- 27 Sakatani T, Kaneda A, Iacobuzio-Donahue CA, *et al.* Loss of imprinting of *Igf2* Alters Intestinal Maturation and Tumorigenesis in Mice. *Science* 2005; **307**:1976-1978.
- 28 Cassidy SB, Dykens E, Williams CA. Prader-Willi and Angelman syndromes: sister imprinted disorders. *Am J Med Genet* 2000; **97**:136-146.
- 29 Matouk IJ, DeGroot N, Mezan S, *et al.* The H19 non-coding RNA is essential for human tumor growth. *PLoS ONE* 2007; **2**:e845. doi: 10.1371/journal.pone.0000845.
- 30 Surani MA, Barton SC. Development of gynogenetic eggs in the mouse: Implications for parthenogenetic embryos. *Science* 1983; **222**:1034-1036.
- 31 Allen ND, Logan K, Lally G, Drage DJ, Norris ML, Keverne EB. Distribution of parthenogenetic cells in the mouse brain and their influence on brain development and behavior. *Proc Natl Acad Sci U S A.* 1995; **92**:10782-10786.
- 32 Kono T, Obata Y, Yoshimzu T, Nakahara T, Carroll J. Epigenetic modifications during oocyte growth correlates with extended parthenogenetic development in the mouse. *Nat Genet* 1996; **13**:91-94.
- 33 Kono T, Sotomaru Y, Katsuzawa Y, Dandolo L. Mouse parthenogenetic embryos with monoallelic H19 expression can develop to day 17.5 of gestation. *Dev Biol* 2002; **243**:294-300.
- 34 Kono T, Obata Y, Wu Q, *et al.* Birth of parthenogenetic mice that can develop to adulthood. *Nature* 2004; **428**:860-864.
- 35 Hammond HA, Jin L, Zhong Y, Caskey CT, Chakraborty R. Evaluation of 13 short tandem repeat loci for use in personal identification applications. *Am J Hum Genet* 1994; **55**:175-189.
- 36 Smith RN. Accurate size comparison of short tandem repeat alleles amplified by PCR. *Biotechniques.* 1995; **18**:122-128.
- 37 Hwang WS, Ryu YJ, Park JH, *et al.* Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst. *Science* 2004; **303**:1669-1674.
- 38 Stevens LC, Vamum DS, Eicher EM. Viable chimaeras produced from normal and parthenogenetic mouse embryos. *Nature* 1977; **269**:515-517.
- 39 Fundele R, Norris ML, Barton SC, Reik W, Surani MA. Systematic elimination of parthenogenetic cells in mouse chimeras. *Development* 1989; **106**:29-35.